Organogenesis to merge to create $673M company: 4 notes

Biologics

Avista Healthcare Public Acquisition will merge with the regenerative medicine company Organogenesis.

Here are four things to know:

1. Organogenesis will become a wholly owned subsidiary of Avista.

2. Avista Capital Partners' affiliates agreed to invest $92 million in the combined company in conjunction with the transaction.

3. The combined company's anticipated initial enterprise value is approximately $673 million.

4. Organogenesis offers bioactive and acellular biomaterials products in advanced wound care, sports medicine and surgical biologics, including orthopedics and spine.

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Whitepapers